130 related articles for article (PubMed ID: 10667479)
1. Evaluation of some tissue and serum biomarkers in prostatic carcinoma among Egyptian males.
Ahmed MI; Abd-Elmotelib F; Farag RM; Ziada NA; Khalifa A
Clin Biochem; 1999 Aug; 32(6):439-45. PubMed ID: 10667479
[TBL] [Abstract][Full Text] [Related]
2. The relation of beclin 1 and bcl-2 expressions in high grade prostatic intraepithelial neoplasia and prostate adenocarcinoma: a tissue microarray study.
Baspinar S; Bircan S; Orhan H; Kapucuoglu N; Bozkurt KK
Pathol Res Pract; 2014 Jul; 210(7):412-8. PubMed ID: 24690321
[TBL] [Abstract][Full Text] [Related]
3. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.
Iacopino F; Angelucci C; Lama G; Zelano G; La Torre G; D'Addessi A; Giovannini C; Bertaccini A; Macaluso MP; Martorana G; Sica G
Anticancer Res; 2006; 26(3A):1849-54. PubMed ID: 16827116
[TBL] [Abstract][Full Text] [Related]
5. The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan.
Wu TT; Hsu YS; Wang JS; Lee YH; Huang JK
J Urol; 2003 Jul; 170(1):78-81. PubMed ID: 12796649
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
7. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
8. IMPORTANCE OF APOPTOSIS MARKERS (MDM2, BCL-2 AND Bax) IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER.
Saker Z; Tsintsadze O; Jiqia I; Managadze L; Chkhotua A
Georgian Med News; 2015 Dec; (249):7-14. PubMed ID: 26719543
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
10. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
11. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
13. PSMA/PSA ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer.
Jemaa AB; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
J Immunoassay Immunochem; 2014; 35(1):48-59. PubMed ID: 24063616
[TBL] [Abstract][Full Text] [Related]
14. [IDENTIFICATION OF A NEW DIAGNOSTIC MARKERS OF PROSTATIC CANCER, USING NOTI-MICROCHIPS].
Vozianov SO; Kashuba VI; Grygorenko VM; Gordiyuk VV; Danylets RO; Bondarenko YM; Vikarchuk MV
Klin Khir; 2016 Apr; (4):54-7. PubMed ID: 27434957
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-Mesenchymal Transition Markers β-catenin, Snail, and E-Cadherin do not Predict Disease Free Survival in Prostate Adenocarcinoma: a Prospective Study.
Ipekci T; Ozden F; Unal B; Saygin C; Uzunaslan D; Ates E
Pathol Oncol Res; 2015 Sep; 21(4):1209-16. PubMed ID: 26037169
[TBL] [Abstract][Full Text] [Related]
16. Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation.
Iemelynova AA; Grygorenko VM; Cheremuha SV; Romanenko AM
Exp Oncol; 2009 Dec; 31(4):246-9. PubMed ID: 20010526
[TBL] [Abstract][Full Text] [Related]
17. DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.
Berner A; Waere H; Nesland JM; Paus E; Danielsen HE; Fosså SD
Br J Urol; 1995 Jan; 75(1):26-32. PubMed ID: 7531589
[TBL] [Abstract][Full Text] [Related]
18. Reverse transcriptase-PCR analysis of apoptosis-regulating gene expression in human benign prostatic hyperplasia.
Angelucci C; Iacopino F; Lama G; Zelano G; Gianesini G; Sica G; Bono AV
Anticancer Res; 2005; 25(6B):3937-41. PubMed ID: 16309180
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
20. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens.
De Marzo AM; Knudsen B; Chan-Tack K; Epstein JI
Urology; 1999 Apr; 53(4):707-13. PubMed ID: 10197845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]